| Outcome Measures: |
Primary: Occurrence of adverse events after a single administration of BPS804, Adverse events will be counted within each treatment and study part. The numbers and percentages of adverse events will be tabulated by body system, preferred term, and severity., 17 weeks | Secondary: Pharmacokinetic (PK) of BPS804 in serum: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, AUClast: The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, Pre-dose, and 2, 24, 44, 48, 168 hours and 15, 22, 29, 57, and 85 days after dosing|PK of BPS804 in serum: area under the serum concentration-time curve from time zero to infinity, AUCinf: The area under the serum concentration-time curve from time zero to infinity, Pre-dose, and 2, 24, 44, 48, 168 hours and 15, 22, 29, 57, and 85 days after dosing|PK of BPS804 in serum: observed maximum serum concentration following drug administration, Cmax: The observed maximum serum concentration following drug administration, Pre-dose, and 2, 24, 44, 48, 168 hours and 15, 22, 29, 57, and 85 days after dosing|PK of BPS804 in serum: terminal elimination half-life, T1/2: The terminal elimination half-life, Pre-dose, and 2, 24, 44, 48, 168 hours and 15, 22, 29, 57, and 85 days after dosing|PK of BPS804 in serum: time to reach the maximum concentration after drug administration, Tmax: The time to reach the maximum concentration after drug administration, Pre-dose, and 2, 24, 44, 48, 168 hours and 15, 22, 29, 57, and 85 days after dosing|Concentration of BPS804 in dialysate 48 hours after dosing, Quantify BPS804 in dialysate 48 hours after dosing to assess any impact of dialysis on BPS804, Day 3, 48 hours post dosing
|
